Anti-PD-L1 antibody and use thereof
An antibody that binds to the PD-L1 protein or CD137 protein, an antigen-binding fragment or a variant thereof, as well as a bispecific antibody that can bind to both the PD-L1 protein and the CD137 protein. The bispecific antibody has a strong ability to specifically recognize the PD-L1 protein and the CD137 protein, and can enhance T-cell activity. The antibody or the antigen-binding fragment or the variant thereof and the bispecific antibody may be used in the prevention and treatment of tumors.
1. An antibody or an antigen binding fragment thereof capable of binding to PD-L1 protein, comprising a light chain variable region VL which comprises LCDRI-3 and a heavy chain variable region VH which comprises HCDRI-3, wherein said antibody or antigen binding fragment thereof comprises amino acid sequences selected from any one of the following groups:
(a) LCDR1: SEQ ID NO:54, LCDR2: SEQ ID NO:60, LCDR3: SEQ ID NO:63, HCDR1: SEQ ID NO:46, HCDR2: SEQ ID NO:48 and HCDR3: SEQ ID NO:50;
(b) LCDR1: SEQ ID NO:55, LCDR2: SEQ ID NO:60, LCDR3: SEQ ID NO:64, HCDR1: SEQ ID NO:47, HCDR2: SEQ ID NO:48 and HCDR3: SEQ ID NO: 51;
(c) LCDR1: SEQ ID NO:55, LCDR2: SEQ ID NO:60, LCDR3: SEQ ID NO:64, HCDR1: SEQ ID NO:47, HCDR2: SEQ ID NO:48 and HCDR3: SEQ ID NO:52;
(d) LCDRI: SEQ ID NO:56, LCDR2: SEQ ID NO:61, LCDR3: SEQ ID NO:64, HCDR1: SEQ ID NO:47, HCDR2: SEQ ID NO:48 and HCDR3: SEQ ID NO:52;
(e) LCDRI: SEQ ID NO:57, LCDR2: SEQ ID NO:61, LCDR3: SEQ ID NO:64, HCDRI: SEQ ID NO:47, HCDR2: SEQ ID NO:48 and HCDR3: SEQ ID NO:52; and
(f) LCDR1: SEQ ID NO:58, LCDR2: SEQ ID NO:61, LCDR3: SEQ ID NO:64, HCDRI: SEQ ID NO:47, HCDR2: SEQ ID NO:48 and HCDR3: SEQ ID NO:52.
2. The antibody or antigen binding fragment thereof of claim 1 , wherein said heavy chain variable region VH comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 9, SEQ ID NO: 31 and SEQ ID NO: 35, and said light chain variable region VL comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 11, SEQ ID NO: 33, SEQ ID NO: 37, SEQ ID NO: 39 and SEQ ID NO: 41.
3. The antibody or antigen binding fragment thereof of claim 1 , comprising an antibody light chain or a fragment thereof and an antibody heavy chain or a fragment thereof, wherein said antibody light chain or fragment thereof comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 15, SEQ ID NO: 34, SEQ ID NO: 38, SEQ ID NO: 40 and SEQ ID NO: 42, and said antibody heavy chain or fragment thereof comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 13, SEQ ID NO: 32 and SEQ ID NO: 36.
4. A bispecific antibody, comprising a first targeting moiety that specifically binds to a PD-L1 protein, wherein the first targeting moiety comprises the antibody or antigen binding fragment thereof of claim 1 .
5. The bispecific antibody of claim 4 , comprising a second targeting moiety that specifically binds to a CD137 protein, wherein the second targeting moiety comprises an antibody or an antigen binding fragment thereof, wherein the antibody that binds to CD137 comprises an antibody light chain or fragment thereof which comprises LCDR1-3 sequentially comprising SEQ ID NOs: 80-82 and an antibody heavy chain or fragment thereof which comprises HCDR1-3 sequentially comprising SEQ ID NOs: 77-79.
6. The bispecific antibody of claim 5 , wherein the antibody that binds to the CD137 protein comprises an scFv, and wherein the scFv comprises the amino acid sequence of SEQ ID NO: 83.
7. The bispecific antibody of claim 5 , comprising a first polypeptide chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 30, SEQ ID NO: 43, and SEQ ID NO: 44; and a second polypeptide chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 15 and SEQ ID NO: 34, wherein the first polypeptide chain comprises a heavy chain variable region of the antibody that binds to the PD-L1 protein, a heavy chain variable region of the antibody that binds to the CD137 protein, and a light chain variable region of the antibody that binds to the CD137 protein, and wherein the second polypeptide chain comprises a light chain variable region of the antibody that binds to the PD-L1 protein.
8. The bispecific antibody of claim 7 , wherein, in the first polypeptide chain, the heavy chain variable region of the antibody that binds to the PD-L1 protein is located at an N-terminus of the heavy chain variable region of the antibody that binds to the CD137 protein, and the heavy chain variable region of the antibody that binds to the CD137 protein is located at an N-terminus of the light chain variable region of the antibody that binds to the CD137 protein.
9. An isolated nucleic acid molecule which encodes the antibody or antigen binding fragment thereof of claim 1 .
10. An isolated nucleic acid molecule which encodes the bispecific antibody of claim 4 .
11. A vector, comprising the molecule of claim 9 .
12. A cell, comprising the molecule of claim 9 or a vector comprising the molecule.
13. A pharmaceutical composition, comprising the antibody or antigen binding fragment thereof of claim 1 and a pharmaceutically acceptable adjuvant.
14. A pharmaceutical composition, comprising the bispecific antibody of claim 4 and a pharmaceutically acceptable adjuvant.
15. A method of treating a tumor, the method comprising administering the antibody or antigen binding fragment thereof of claim 1 .
16. A method of treating a tumor, the method comprising administering the bispecific antibody of claim 4 .
17. A method of inhibiting the binding of a PD-L1 protein to a PD-1 protein, the method comprising administering the antibody or antigen binding fragment thereof of claim 1 .
18. A method of inhibiting the binding of a PD-L1 protein to a PD-1 protein, the method comprising administering the bispecific antibody of claim 4 .